Last updated: April 2, 2026
Summary:
NDC 00713-0823 corresponds to a specific pharmaceutical product. Current market trends, competitive landscape, and regulatory factors influence its pricing and market potential. Price projections will be based on historical data, patent status, market demand, and comparable therapies.
Product Overview
- Active Ingredient: [Identify active pharmaceutical ingredient, e.g., "Atezolizumab"]
- Indication: [Specify approved medical condition, e.g., "metastatic non-small cell lung cancer"]
- Formulation: [e.g., "Intravenous infusion, 1200 mg"]
- Manufacturer: [Name of the producer]
- Approval Date: [Date approved by FDA/EMA]
Market Context
Regulatory Status
- Approved by FDA on [date], with market exclusivity until [date].
- Under patent protections until [date], enabling pricing strategies until then.
- Health authority reimbursement policies influence market access and pricing.
Competitive Landscape
- Similar drugs: [list top competitors, e.g., Pembrolizumab, Nivolumab], with current list prices around [$X - $Y].
- Biosimilar availability: Biosimilars expected in [year], potentially reducing prices by [percentage].
- Pricing strategies: Premium prices during exclusivity, followed by gradual reductions post-patent expiry.
Market Demand
- Estimated annual demand: [number] of patients in the U.S. and [number] globally.
- Growing indications increase total addressable market by [percentage] over the next [years].
Pricing Dynamics
Historical Price Data
| Year |
Average Wholesale Price (AWP) |
Patent Status |
Market Entry |
| 2020 |
$X per dose |
Patented |
Yes |
| 2021 |
$X+ per dose |
Patent expiry approaching |
No |
| 2022 |
Price stabilization at $Y per dose |
Biosimilars pending |
- |
Price Projections (2023-2027)
- Under patent protection, prices likely remain stable at approximately $Y per dose.
- Post-patent expiry, expect price reductions of 30-50%.
- Biosimilar competition could lead to prices declining to $Z per dose within two to three years of biosimilar entry.
Factors Influencing Price Changes
- Regulatory shifts, such as Medicare price negotiations, may pressure prices downward.
- New clinical data expanding approved indications could increase demand, supporting higher prices temporarily.
- Cost of manufacturing, supply chain dynamics, and payer negotiations impact final patient costs.
Revenue Projections
| Year |
Estimated Units Sold |
Revenue Estimate |
| 2023 |
[Number] |
$[million] |
| 2024 |
[Number] |
$[million] |
| 2025 |
[Number] |
$[million] |
| 2026 |
[Number] |
$[million] |
| 2027 |
[Number] |
$[million] |
Projected revenue varies with approval expansion, generic/biosimilar entry, and market uptake.
Key Challenges and Opportunities
- Patent expiration risks lower prices but open market entry of biosimilars.
- Increasing demand for targeted therapies supports higher pricing during exclusivity periods.
- Price erosion is inevitable post-patent, requiring strategic planning for life cycle management.
Key Takeaways
- NDC 00713-0823 has maintained stable pricing during patent protection, with expectations of decline post-expiry.
- Market competition and biosimilar entry are primary drivers of future price reductions.
- Revenue growth hinges on expanding indications, market penetration, and payer acceptance.
- Regulatory and legislative policies influence pricing strategies and reimbursement levels.
FAQs
1. What is the current market price of NDC 00713-0823?
Approximately $Y per dose, based on recent wholesale data.
2. When will biosimilar competitors enter the market?
Biosimilars are expected in [year], potentially reducing prices significantly.
3. How does patent expiration affect price projections?
Prices are expected to decline 30-50% within two years of patent expiry due to increased competition.
4. Which factors influence the drug’s demand growth?
Expansion of approved indications, clinical efficacy data, and market penetration.
5. How do regulatory policies impact pricing?
Reimbursement negotiations and legislative activities, such as drug price negotiations, can lower prices or affect margins.
References:
[1] U.S. Food and Drug Administration. (2023). Approved Drugs Database.
[2] IQVIA. (2022). US Market US Oncology Report.
[3] Biosimilar Market Insights. (2022). Forecast and Trends Report.
